Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep

Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E3, Canada.
Veterinary Immunology and Immunopathology (Impact Factor: 1.54). 03/2007; 115(3-4):357-68. DOI: 10.1016/j.vetimm.2006.11.013
Source: PubMed


Mucosal delivery of CpG oligodeoxynucleotide (ODN) in mice has been shown to induce potent innate immunostimulatory responses and protection against infection. We evaluated the efficacy of CpG ODN in stimulating systemic innate immune responses in sheep following delivery to the pulmonary mucosa. Intrapulmonary (IPM) administration of B-Class CpG ODN in saline induced transient systemic responses which included increased rectal temperatures, elevated serum 2'5'-A synthetase and haptoglobin concentrations. The ODN dose required to induce detectable systemic responses following IPM delivery could be reduced by approximately 80% if the CpG ODN was administered in 30% emulsigen instead of saline. Intrapulmonary B-Class CpG ODN formulated in 30% emulsigen produced similar effects when compared to those seen following SC injection. These responses were CpG ODN-specific since control GpC ODN did not induce any detectable response. Intrapulmonary administration of both B-Class and the newly described C-Class CpG ODN produced similar effects indicating that both classes of CpG ODN were comparably effective in stimulating innate immune system following mucosal delivery. Administration of CpG ODN directly into the lungs or delivery of CpG ODN via an intratracheal (IT) infusion also produced similar systemic responses. These observations support the conclusion that mucosal delivery of CpG ODN is an effective route for induction of systemic acute phase responses and antiviral effector molecules in large animals, and may be helpful in controlling systemic infections.

7 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Oligodinucleotides containing CpG motifs stimulate vertebrate immune cells in vitro, have proven efficacy in murine disease models and are currently being tested in human clinical trials as therapies for cancer, allergy, and infectious disease. As there are no known immunostimulatory motifs for veterinary species, the potential of CpG DNA as a veterinary pharmaceutical has not been investigated. Here, optimal CpG motifs for seven veterinary and three laboratory species are described. The preferential recognition of a GTCGTT motif was strongly conserved across two vertebrate phyla, although a GACGTT motif was optimal for inbred strains of mice and rabbits. In a subsequent adjuvanticity trial, the in vitro screening methodology was validated in sheep, representing the first demonstration of CpG DNA efficacy in a veterinary species. These results should provide candidate immunostimulant and therapeutic drugs for veterinary use and enable the testing of CpG DNA in large animal models of human disease.
    Full-text · Article · Nov 2001 · Antisense and Nucleic Acid Drug Development
  • [Show abstract] [Hide abstract]
    ABSTRACT: The alloy CePd1-xRhx is a unique example undergoing quantum critical behavior between ferromagnetic CePd (TC=6.6K) and mixed valence CeRh. The negative curvature of TC(x) holds up to x=0.6, followed by a positive tail with the lowest measured TC=0.25K at x=0.80. We report on a detailed investigation within the 0.80⩽x⩽1 range, using specific heat (Cm) and thermal expansion (β) techniques. A change of regime is observed in the T dependence of both parameters at xcr=0.85, from ln(T0/T) to A(x)T-q, with q=0.54 at x=0.87 and the coefficient A(x) vanishing as x→1. Simultaneously, a change of sign in β(T) is observed at xcr. The vanishing Cm/T=A(x)T-q contribution coexists beyond xcr with a Fermi Liquid component.
    No preview · Article · May 2006 · Physica B Condensed Matter
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunostimulatory DNA containing unmethylated CpG motifs is recognized by Toll-like receptor 9, resulting in the activation of innate immune responses that subsequently amplify the adaptive-immune response. Advances in the characterization of Toll-like receptor 9 signaling have identified immunostimulatory sequences (ISS) with distinct biological activities. Numerous animal models have demonstrated that synthetic ISS are effective adjuvants that enhance both humoral and cellular immune responses in diverse indications, ranging from infectious disease to cancer and allergy. An added benefit supporting the use of ISS as a vaccine adjuvant is that the specific activation of a pathway critical to the regulation of the immune response results in minimal toxicity. To date, clinical testing has largely affirmed the potency and safety of ISS-adjuvanted vaccines.
    Preview · Article · Nov 2007 · Expert Review of Vaccines
Show more